ES2287980T3 - Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos. - Google Patents

Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos. Download PDF

Info

Publication number
ES2287980T3
ES2287980T3 ES98943975T ES98943975T ES2287980T3 ES 2287980 T3 ES2287980 T3 ES 2287980T3 ES 98943975 T ES98943975 T ES 98943975T ES 98943975 T ES98943975 T ES 98943975T ES 2287980 T3 ES2287980 T3 ES 2287980T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
composition according
proteins
placebo
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98943975T
Other languages
English (en)
Spanish (es)
Inventor
Annie Bardat
Roland Schmitthauesler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Application granted granted Critical
Publication of ES2287980T3 publication Critical patent/ES2287980T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES98943975T 1997-09-18 1998-09-14 Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos. Expired - Lifetime ES2287980T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9711626 1997-09-18
FR9711626A FR2768341B1 (fr) 1997-09-18 1997-09-18 Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Publications (1)

Publication Number Publication Date
ES2287980T3 true ES2287980T3 (es) 2007-12-16

Family

ID=9511216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98943975T Expired - Lifetime ES2287980T3 (es) 1997-09-18 1998-09-14 Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos.

Country Status (11)

Country Link
US (1) US6242423B1 (de)
EP (1) EP1014948B1 (de)
AT (1) ATE365542T1 (de)
CA (1) CA2304021A1 (de)
CY (1) CY1106769T1 (de)
DE (1) DE69837997T2 (de)
DK (1) DK1014948T3 (de)
ES (1) ES2287980T3 (de)
FR (1) FR2768341B1 (de)
PT (1) PT1014948E (de)
WO (1) WO1999013866A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
US6566575B1 (en) 2000-02-15 2003-05-20 3M Innovative Properties Company Patterned absorbent article for wound dressing
US6977323B1 (en) 2000-02-17 2005-12-20 3M Innovative Properties Company Foam-on-film medical articles
US6716186B1 (en) 2000-08-16 2004-04-06 3M Innovative Properties Company Curable adhesive splints and methods
US6903243B1 (en) 2000-09-08 2005-06-07 3M Innovative Properties Company Multi-layer absorbent wound dressing
US7005143B2 (en) 2002-04-12 2006-02-28 3M Innovative Properties Company Gel materials, medical articles, and methods
US7612248B2 (en) 2002-12-19 2009-11-03 3M Innovative Properties Company Absorbent medical articles
US20050070688A1 (en) 2003-09-26 2005-03-31 3M Innovative Properties Company Reactive hydrophilic oligomers
US7384984B2 (en) 2003-12-10 2008-06-10 3M Innovative Properties Company Reactive hydrophilic oligomers
US7074839B2 (en) * 2004-03-01 2006-07-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent photoinitiator groups
US7342047B2 (en) * 2004-03-02 2008-03-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent unsaturated groups
US7335690B2 (en) 2005-01-25 2008-02-26 3M Innovative Properties Company Crosslinkable hydrophilic materials from polymers having pendent Michael donor groups
US8609131B2 (en) 2005-01-25 2013-12-17 3M Innovative Properties Company Absorbent dressing comprising hydrophilic polymer prepared via Michael reaction
US7981949B2 (en) 2006-05-23 2011-07-19 3M Innovative Properties Company Curable hydrophilic compositions
US20110155620A1 (en) 2009-12-30 2011-06-30 Baxter International Inc. Rapid reconstitution for lyophilized-pharmaceutical suspensions
KR20240168339A (ko) * 2022-03-25 2024-11-29 암젠 인크 자동화된 시각적 검사 시스템용 인공 동결 건조 제품 샘플

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5151511A (en) * 1974-10-25 1976-05-07 Tooru Tatsuhara Aminosanseizai no anteikaho
EP0084705B1 (de) * 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Verfahren zur Herstellung von festen Formgegenständen
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2751177B1 (fr) * 1996-07-17 1998-08-28 Morelle Jean Compositions exemptes de proteines et de peptides obtenues a partir de toutes proteines animales, destinees a l'alimentation animale et humaine, ainsi qu'a l'usage cosmetique pharmaceutique et agricole
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Also Published As

Publication number Publication date
ATE365542T1 (de) 2007-07-15
DK1014948T3 (da) 2007-09-24
WO1999013866A1 (fr) 1999-03-25
PT1014948E (pt) 2007-07-18
DE69837997T2 (de) 2008-02-28
FR2768341B1 (fr) 2000-04-14
DE69837997D1 (de) 2007-08-09
EP1014948B1 (de) 2007-06-27
EP1014948A1 (de) 2000-07-05
US6242423B1 (en) 2001-06-05
FR2768341A1 (fr) 1999-03-19
CA2304021A1 (fr) 1999-03-25
CY1106769T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
ES2287980T3 (es) Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos.
ES2574761T3 (es) Formulaciones para el tratamiento de la diabetes
ES2809178T5 (es) Formulaciones de liberación sostenida que usan portadores no acuosos
ES2257428T3 (es) Composiciones farmaceuticas de liberacion sostenida para administracion parenteral de compuestos hidrofilos.
ES2338218T3 (es) Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
EP0858325B1 (de) Lyophilisierte stabile pharmazeutische formulierung
ES2227727T3 (es) Preparados farmaceuticos liofilizados estables de anticuerpos monoclonales o policlonales.
ES2527225T3 (es) Forma de dosificación oral sólida que contiene nanopartículas y proceso para su formulación utilizando gelatina de pescado
AU631730B2 (en) Stabilized gonadotropin containing preparations
ES2532007T3 (es) Formulación para combinación de HGH y rhIGF-1
CN1170586C (zh) 膜海鞘素化合物的药物制剂
ES2600628T3 (es) Composición líquida de racecadotril
PT650354E (pt) Solucoes solidas e liquidas de drogas pouco soluveis em agua
ES2558705T3 (es) Nueva formulación de epoprostenol y procedimiento de fabricación de la misma
ES2359856T3 (es) Formulación parenteral estable que contiene un inhibidor de vsr de una estructura de benzodiazepina.
KR20080078000A (ko) 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제
JP2006137678A (ja) インターロイキン−２組成物
JP2011157393A (ja) 組換え炭水化物結合ポリペプチドの安定型凍結乾燥生薬製剤
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
JPH05331071A (ja) カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
ES2377352T3 (es) Nuevas composiciones a base de taxoides
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
ES2244043T3 (es) Composicion liofilizada de mp52 humana de factor morfogenetico oseo.
CN115364060A (zh) 一种冻干药物制剂及其用途
ES2231159T3 (es) Composiciones terapeuticas que contienen analogos de glutation.